Article

Familial Alzheimer disease: Decreases in CSF A beta(42) levels precede cognitive decline

Department of Neurology, University of Massachusetts Medical School, 55 Lake Ave. N., Worcester, MA 01655, USA.
Neurology (Impact Factor: 8.3). 08/2005; 65(2):323-5. DOI: 10.1212/01.wnl.0000171397.32851.bc
Source: PubMed

ABSTRACT CSF amyloid beta-peptide 42 (A beta(42)) levels in presymptomatic subjects with pathogenic mutations in the PS1 gene are significantly lower than in an age-matched control group. Consequently, in these subjects, there is a window of opportunity estimated as at least 4 to 12 years to evaluate the ability of any putative prophylactic therapy to decrease, arrest, or reverse abnormalities in A beta(42) metabolism many years before clinical symptoms of Alzheimer disease are otherwise likely to occur.

0 Bookmarks
 · 
86 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Subjective cognitive impairment may be a very early at-risk period of the continuum of dementia. However, it is difficult to discriminate at-risk states from normal aging. Thus, detection of the early pathological changes in the subjective cognitive impairment period is needed. To elucidate these changes, we employed diffusion tensor imaging and volumetry analysis, and compared subjective cognitive impairment with normal, mild cognitive impairment and Alzheimer's disease. The subjects in this study were 39 Alzheimer's disease, 43 mild cognitive impairment, 28 subjective cognitive impairment and 41 normal controls. There were no statistically significant differences between the normal control and subjective cognitive impairment groups in all measures. Alzheimer's disease and mild cognitive impairment had the same extent of brain atrophy and diffusion changes. These results are consistent with the hypothetical model of the dynamic biomarkers of Alzheimer's disease.
    PLoS ONE 08/2014; 9(8):e104007. DOI:10.1371/journal.pone.0104007 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Current research criteria for Alzheimer's disease (AD) include cerebrospinal fluid (CSF) biomarkers into the diagnostic algorithm. However, spreading their use to the clinical routine is still questionable. Objective: To provide an updated, systematic and critical review on the diagnostic utility of the CSF core biomarkers for AD. Data sources: MEDLINE, PreMedline, EMBASE, PsycInfo, CINAHL, Cochrane Library, and CRD. Eligibility criteria: (1a) Systematic reviews with meta-analysis; (1b) Primary studies published after the new revised diagnostic criteria; (2) Evaluation of the diagnostic performance of at least one CSF core biomarker. Results: The diagnostic performance of CSF biomarkers is generally satisfactory. They are optimal for discriminating AD patients from healthy controls. Their combination may also be suitable for mild cognitive impairment (MCI) prognosis. However, CSF biomarkers fail to distinguish AD from other forms of dementia. Limitations: (1) Use of clinical diagnosis as standard instead of pathological postmortem confirmation; (2) variability of methodological aspects; (3) insufficiently long follow-up periods in MCI studies; and (4) lower diagnostic accuracy in primary care compared with memory clinics. Conclusion: Additional work needs to be done to validate the application of CSF core biomarkers as they are proposed in the new revised diagnostic criteria. The use of CSF core biomarkers in clinical routine is more likely if these limitations are overcome. Early diagnosis is going to be of utmost importance when effective pharmacological treatment will be available and the CSF core biomarkers can also be implemented in clinical trials for drug development.
    Frontiers in Aging Neuroscience 01/2014; 6:47. DOI:10.3389/fnagi.2014.00047 · 2.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: with a sensitivity of 95% and a specificity of 87% [5]. Bateman et al., analyzed data from 128 participants who underwent baseline clinical and cognitive assessments, brain imaging and CSF and blood tests. Concentrations of amyloid-beta Aβ42in the CSF appeared to decline 25 years before expected symptomonset. Aβ deposition, as measured by PET with the use of Pittsburgh compound B (PIB), was detected 15 years before expected symptomonset. Increased concentrations of tau protein in the CSF and an increase in brain atrophy were detected 15 years before expected symptomonset. They found that autosomal dominant Alzheimer's disease was associated with a several pathophysiological changes over decades in CSF biomarkers of AD [6]. CSF or blood plasma remain the most promising sources for AD biomarkers as compared to brain tissue. Blood Biomarkers CSF limits the ability to access DNA and RNA, In contrast blood's biomarkers provide a rich source of genetic materials and proteomic species for investigations. Several data indicate that miRNAs are deregulated in brain, CSF, and in blood, therefore they might be used as biomarkers in the diagnosis of AD. Kiddle et al., used Soma Logic's SOMA scan proteomics technology, they were able to conduct a large-scale replication study for 94 of the 163 candidate biomarkers from 21 published studies in plasma samples. Nine of the 94 previously reported candidates were associated to AD phenotype. These proteins may be considered as a biomarker set for further investigations [7]. Lin Tan et al., investigated the potential role of serum miRNAs as diagnostic biomarkers for AD. They indicated that serum miR-125b may serve as a useful noninvasive biomarker for AD [8]. Leidinger et al., revealed the involvement of 12 miRNAs in AD. They differentiated between AD and controls with an accuracy of 93%, a specificity of 95% and a sensitivity of 92% [9]. Galimberti et al., demonstrated that cell-free miR-125b serum levels are decreased in serum from patients with AD as compared with non-inflammatory neurological controls with an accuracy of 82% [10]. Blood is an attractive source for biomarkers due to minimal discomfort to the patient. Unfortunately the sensitivity and specificity of blood biomarkers remain lower than those from CSF. Ray et al., found 18 signaling proteins in blood plasma that can beused to classify Alzheimer patients from control subjects with 90% accuracy and to identify patients who had mild cognitive impairment that progressed to AD 2–6 years later [11]. Lundstrom et al., revealed the alteration of blood plasma IgG Fc glycans in AD which can discriminate cognitively normal (CN) subjects from those with MCI and AD, with a sensitivity of 89.3% and a specificity of 79.1% [12].